City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases ac…
| Métrica | CTY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.7% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.4% | — |
| FCF Margin | — | -10.6% | — |
| ROE | — | -36.3% | — |
| ROA | — | -30.0% | — |
| Current Ratio | — | 2.68 | — |
| Debt / Equity | — | 0.28 | — |
CITY THERAPEUTICS, INC. cotiza a 21.65 USD y tiene una capitalización bursátil de $1.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud